# Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/ramucirumab-versus-placebo-as-second-line-treatment-in-patients-with-advanced/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Andrew X. Zhu,Joon Oh Park,Baek‐Yeol Ryoo,Chia-Jui Yen,Ronnie T. P. Poon,Davide Pastorelli,Jean-Frédéric Blanc,Hyun Cheol Chung,Ari David Baron,Túlio Pfiffer,Takuji Okusaka,Kateřina Kubáčková,Jörg Trojan,Javier Sastre,Ian Chau,Shao-Chun Chang,Paolo Abada,Ling Yang,Jonathan D. Schwartz,Masatoshi Kudo |
| Citations | 846 |
| DOI | 10.1016/s1470-2045(15)00050-9 |
| Fields | Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | http://www.sciencedirect.com/science/article/pii/S1470204515000509 |
| OpenAlex ID | https://openalex.org/W1828082159 |
| PMID | 26095784 |
| Type | article |
| Year | 2015 |

## Paper authors

- [Jonathan D. Schwartz](https://scholariq.org/researchers/jonathan-d-schwartz/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)

## Paper topics

- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Liver physiology and pathology](https://scholariq.org/topics/liver-physiology-and-pathology/)
- [Cancer Mechanisms and Therapy](https://scholariq.org/topics/cancer-mechanisms-and-therapy/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.